Cosmo — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Cosmo is a diversified life sciences company leveraging AI and digital health to advance therapeutics and technologies in dermatology, gastroenterology, and medical AI. With a business model encompassing proprietary drug development and contract manufacturing services, it targets significant unmet needs in gut and skin health. The company appears to be in a commercial stage, given its CDMO operations and focus on bringing therapies to market through partnerships.

GastroenterologyDermatology

Technology Platform

AI and digital health platform for accelerating therapeutic development and medical technology, integrated with small molecule manufacturing capabilities (CDMO).

Pipeline

5

5 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
Methylene Blue MMX® + Placebo	Colorectal Cancer	Phase 3
Methylene Blue MMX tablets	Colorectal Cancer	Phase 2
CB-10-01 (Transgenic Lymphocyte Immunization)	Stage IIIB Skin Melanoma	Phase 2
Transgenic Lymphocyte Immunization Vaccine (TLI)	Prostatic Neoplasms	Phase 1
Rifamycin SV-MMX® 600	Healthy	Phase 1

Opportunities

The convergence of AI with drug development and medical devices presents a massive growth frontier, allowing for faster innovation and personalized care.

Large, chronic markets in gastroenterology and dermatology offer sustained demand for new and improved therapeutic solutions.

The CDMO model provides a resilient service-based revenue stream and deepens industry partnerships.

Risk Factors

The company's complex, hybrid business model spanning pharma, tech, and services increases operational and integration challenges.

Both its therapeutic pipelines and MedTech AI face significant regulatory, clinical, and competitive risks.

As a public but smaller player, it may face resource constraints compared to larger, pure-play pharmaceutical or tech competitors.

Competitive Landscape

In dermatology and gastroenterology, Cosmo competes with large pharmaceutical companies (e.g., AbbVie, Johnson & Johnson, Pfizer) and specialized biotechs. In MedTech AI, it competes with both established medical device companies and agile tech startups. Its CDMO business competes with a global field of contract manufacturers ranging from giants like Lonza to regional specialists.

More companies in Small Molecule Drugs →More companies in Ireland →